Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) Company Bio
Horizon Pharma plc engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company was founded in 2005 and is based in Dublin, Ireland.
HZNP Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Horizon Therapeutics Public Ltd Co with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Horizon Therapeutics Public Ltd Co ranked in the 22th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 74.67%. The most interesting components of our discounted cash flow analysis for Horizon Therapeutics Public Ltd Co ended up being:
The company's balance sheet shows it gets 95% of its capital from equity, and 5% of its capital from debt. Notably, its equity weight is greater than 68.63% of US equities in the Healthcare sector yielding a positive free cash flow.
The business' balance sheet suggests that 5% of the company's capital is sourced from debt; this is greater than only 17.7% of the free cash flow producing stocks we're observing.
Horizon Therapeutics Public Ltd Co's effective tax rate, as measured by taxes paid relative to net income, is at 189 -- greater than 98.86% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Horizon Therapeutics Public Ltd Co? See CNC, IDXX, MDT, BSX, and EHC.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced updates on its 2020 financial results, TEPEZZA supply and new KRYSTEXXA trials. “Amid the most challenging environment we have ever faced, we had a record year of performance, exceeding our full-year 2020 net sales and adjusted EBITDA guidance, driven by the significant outperformance of TEPEZZA and the strong second-half performance of KRYSTEXXA,” said Tim Walbert, chairman, president and chief executive officer,
Selecta Biosciences (SELB) value proposition is straightforward: many drugs produce an immune response that limits their efficacy while enhancing their adverse events profile. That means, you have a disease, and you take a drug to treat that disease, however, your body thinks of that drug as an enemy, and tries...
Avisol Capital Partners on Seeking Alpha | December 25, 2020
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the 39th Annual J.P. Morgan Healthcare Conference. Tim Walbert, chairman, president and chief executive officer, will present at 11:40 a.m. ET on Jan. 12, 2021.